Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical Trial to Evaluate TPST-1495 as a monotherapy and in combination with a checkpoint inhibitor in Patients with Advanced Cancers

Next Previous
Trial Profile

A phase I clinical Trial to Evaluate TPST-1495 as a monotherapy and in combination with a checkpoint inhibitor in Patients with Advanced Cancers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Checkpoint kinase inhibitors (Primary) ; TPST 1495 (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Tempest Therapeutics

Most Recent Events

  • 12 Aug 2021 According to a Tempest Therapeutics media release, the company expect to initiate this study prior to the end of 2021.
  • 29 Mar 2021 According to a Tempest Therapeutics media release, company expects data from planned monotherapy dose expansion and combination studies in 2022.
  • 30 Jan 2020 According to a Tempest Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for TPST-1495.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top